{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,8]],"date-time":"2026-09-08T03:30:34Z","timestamp":1788838234440,"version":"build-2803163510"},"reference-count":158,"publisher":"Elsevier","isbn-type":[{"value":"9780128231210","type":"print"}],"license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00c3\u00a7\u00c3\u00a3o para a Ci\u00c3\u00aancia e a Tecnologia","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008530","name":"European Regional Development Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008530","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011929","name":"Programa Operacional Tem\u00c3\u00a1tico Factores de Competitividade","doi-asserted-by":"publisher","award":["UID\/NEU\/04539\/2019"],"award-info":[{"award-number":["UID\/NEU\/04539\/2019"]}],"id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011929","name":"Programa Operacional Tem\u00c3\u00a1tico Factores de Competitividade","doi-asserted-by":"publisher","award":["CENTRO-01-0145-FEDER-000012"],"award-info":[{"award-number":["CENTRO-01-0145-FEDER-000012"]}],"id":[{"id":"10.13039\/501100011929","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007395","name":"Instituto Nacional de Ci\u00c3\u00aancia e Tecnologia para Excitotoxicidade e Neuroprote\u00c3\u00a7\u00c3\u00a3o","doi-asserted-by":"publisher","award":["UIDB\/04539\/2020"],"award-info":[{"award-number":["UIDB\/04539\/2020"]}],"id":[{"id":"10.13039\/501100007395","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020]]},"DOI":"10.1016\/bs.irn.2020.02.010","type":"book-chapter","created":{"date-parts":[[2020,8,11]],"date-time":"2020-08-11T08:12:00Z","timestamp":1597133520000},"page":"37-64","source":"Crossref","is-referenced-by-count":53,"title":["Antidiabetic drugs for Alzheimer's and Parkinson's diseases: Repurposing insulin, metformin, and thiazolidinediones"],"prefix":"10.1016","member":"78","reference":[{"issue":"90","key":"10.1016\/bs.irn.2020.02.010_bb0010","first-page":"277","article-title":"Antidiabetic drugs and their potential role in treating mild cognitive impairment and Alzheimer's disease","volume":"16","author":"Alagiakrishnan","year":"2013","journal-title":"Discovery Medicine"},{"key":"10.1016\/bs.irn.2020.02.010_bb0015","doi-asserted-by":"crossref","first-page":"630865","DOI":"10.4061\/2011\/630865","article-title":"The pathogenesis of Alzheimer's disease: A reevaluation of the \u201camyloid cascade hypothesis\u201d","volume":"2011","author":"Armstrong","year":"2011","journal-title":"International Journal of Alzheimer's Disease"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0020","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1001\/archneur.61.5.661","article-title":"Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function","volume":"61","author":"Arvanitakis","year":"2004","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2020.02.010_bb0025","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.pneurobio.2016.10.001","article-title":"Insulin resistance and Parkinson's disease: A new target for disease modification?","volume":"145\u2013146","author":"Athauda","year":"2016","journal-title":"Progress in Neurobiology"},{"issue":"7","key":"10.1016\/bs.irn.2020.02.010_bb0030","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.1007\/s00415-018-8768-0","article-title":"Intranasal insulin in Alzheimer's dementia or mild cognitive impairment: A systematic review","volume":"265","author":"Avgerinos","year":"2018","journal-title":"Journal of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb9000","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1001\/archneurol.2010.225","article-title":"Insulin resistance and Alzheimer-like reductions in regional cerebral glucose metabolism for cognitively normal adults with prediabetes or early type 2 diabetes","volume":"68","author":"Baker","year":"2011","journal-title":"Archives of Neurology"},{"key":"10.1016\/bs.irn.2020.02.010_bb0035","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.freeradbiomed.2015.12.012","article-title":"Impairment of biliverdin reductase-A promotes brain insulin resistance in Alzheimer disease: A new paradigm","volume":"91","author":"Barone","year":"2016","journal-title":"Free Radical Biology & Medicine"},{"issue":"6","key":"10.1016\/bs.irn.2020.02.010_bb0040","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1016\/j.cmet.2016.05.011","article-title":"Metformin as a tool to target aging","volume":"23","author":"Barzilai","year":"2016","journal-title":"Cell Metabolism"},{"issue":"11","key":"10.1016\/bs.irn.2020.02.010_bb0045","doi-asserted-by":"crossref","first-page":"8754","DOI":"10.1007\/s12035-018-1025-9","article-title":"Diabetes mellitus as a risk factor for Parkinson's disease: A molecular point of view","volume":"55","author":"Biosa","year":"2018","journal-title":"Molecular Neurobiology"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0050","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1007\/s10072-003-0108-0","article-title":"DJ-1(PARK7), a novel gene for autosomal recessive, early onset parkinsonism","volume":"24","author":"Bonifati","year":"2003","journal-title":"Neurological Sciences"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0055","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1111\/j.1600-0404.2011.01556.x","article-title":"Glucose metabolism in small subcortical structures in Parkinson's disease","volume":"125","author":"Borghammer","year":"2012","journal-title":"Acta Neurologica Scandinavica"},{"issue":"11","key":"10.1016\/bs.irn.2020.02.010_bb0060","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1002\/mds.27128","article-title":"Glitazone use associated with reduced risk of Parkinson's disease","volume":"32","author":"Brakedal","year":"2017","journal-title":"Movement Disorders"},{"issue":"7","key":"10.1016\/bs.irn.2020.02.010_bb0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001854","article-title":"Glitazone treatment and incidence of Parkinson's disease among people with diabetes: A retrospective cohort study","volume":"12","author":"Brauer","year":"2015","journal-title":"PLoS Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0070","doi-asserted-by":"crossref","first-page":"615","DOI":"10.1046\/j.1471-4159.2002.00990.x","article-title":"Protective action of the peroxisome proliferator-activated receptor-gamma agonist pioglitazone in a mouse model of Parkinson's disease","volume":"82","author":"Breidert","year":"2002","journal-title":"Journal of Neurochemistry"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0075","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1002\/ana.20474","article-title":"Mitochondrial abnormalities in Alzheimer brain: Mechanistic implications","volume":"57","author":"Bubber","year":"2005","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2020.02.010_bb0080","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/j.arr.2017.08.003","article-title":"Metformin reduces all-cause mortality and diseases of ageing independent of its effect on diabetes control: A systematic review and meta-analysis","volume":"40","author":"Campbell","year":"2017","journal-title":"Ageing Research Reviews"},{"issue":"12","key":"10.1016\/bs.irn.2020.02.010_bb0085","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1002\/iub.1098","article-title":"The impairment of insulin signaling in Alzheimer's disease","volume":"64","author":"Candeias","year":"2012","journal-title":"IUBMB Life"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0090","doi-asserted-by":"crossref","first-page":"483","DOI":"10.3233\/JAD-2009-1155","article-title":"Insulin is a two-edged knife on the brain","volume":"18","author":"Cardoso","year":"2009","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/bs.irn.2020.02.010_bb0095","series-title":"Advances in Neurobiology","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/978-3-319-63260-5_5","article-title":"Diabesity and brain energy metabolism: The case of Alzheimer's disease","volume":"vol. 19","author":"Cardoso","year":"2017"},{"key":"10.1016\/bs.irn.2020.02.010_bb0100","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.neuroscience.2011.07.046","article-title":"Rosiglitazone decreases peroxisome proliferator receptor-gamma levels in microglia and inhibits TNF-alpha production: New evidences on neuroprotection in a progressive Parkinson's disease model","volume":"194","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0105","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1517\/13543784.2015.963195","article-title":"Thiazolidinediones under preclinical and early clinical development for the treatment of Parkinson's disease","volume":"24","author":"Carta","year":"2015","journal-title":"Expert Opinion on Investigational Drugs"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0110","doi-asserted-by":"crossref","first-page":"1234","DOI":"10.2337\/db11-1186","article-title":"Metabolic alterations induced by sucrose intake and Alzheimer's disease promote similar brain mitochondrial abnormalities","volume":"61","author":"Carvalho","year":"2012","journal-title":"Diabetes"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0115","doi-asserted-by":"crossref","first-page":"623","DOI":"10.3233\/JAD-130005","article-title":"Type 2 diabetic and Alzheimer's disease mice present similar behavioral, cognitive, and vascular anomalies","volume":"35","author":"Carvalho","year":"2013","journal-title":"Journal of Alzheimer's Disease"},{"issue":"8","key":"10.1016\/bs.irn.2020.02.010_bb0120","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1016\/j.bbadis.2015.05.001","article-title":"Alzheimer's disease and type 2 diabetes-related alterations in brain mitochondria, autophagy and synaptic markers","volume":"1852","author":"Carvalho","year":"2015","journal-title":"Biochimica et Biophysica Acta"},{"issue":"12","key":"10.1016\/bs.irn.2020.02.010_bb0125","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.2337\/dc11-1584","article-title":"Diabetes and risk of Parkinson's disease: A systematic review and meta-analysis","volume":"34","author":"Cereda","year":"2011","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0130","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1007\/s12640-017-9809-7","article-title":"Intranasal insulin ameliorates cerebral hypometabolism, neuronal loss, and astrogliosis in streptozotocin-induced Alzheimer's rat model","volume":"33","author":"Chen","year":"2018","journal-title":"Neurotoxicity Research"},{"key":"10.1016\/bs.irn.2020.02.010_bb0135","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.expneurol.2018.09.008","article-title":"Metformin attenuates diabetes-induced tau hyperphosphorylation in vitro and in vivo by enhancing autophagic clearance","volume":"311","author":"Chen","year":"2019","journal-title":"Experimental Neurology"},{"key":"10.1016\/bs.irn.2020.02.010_bb0140","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1016\/j.expneurol.2014.06.004","article-title":"Intranasal insulin restores insulin signaling, increases synaptic proteins, and reduces Abeta level and microglia activation in the brains of 3xTg-AD mice","volume":"261","author":"Chen","year":"2014","journal-title":"Experimental Neurology"},{"issue":"10","key":"10.1016\/bs.irn.2020.02.010_bb0145","doi-asserted-by":"crossref","first-page":"3907","DOI":"10.1073\/pnas.0807991106","article-title":"Antidiabetic drug metformin (GlucophageR) increases biogenesis of Alzheimer's amyloid peptides via up-regulating BACE1 transcription","volume":"106","author":"Chen","year":"2009","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"10.1016\/bs.irn.2020.02.010_bb0150","article-title":"Mitochondrial dysfunction plays a key role in the development of neurodegenerative diseases in diabetes","author":"Cheng","year":"2019","journal-title":"American Journal of Physiology. Endocrinology and Metabolism"},{"issue":"10","key":"10.1016\/bs.irn.2020.02.010_bb0155","doi-asserted-by":"crossref","first-page":"1299","DOI":"10.1093\/gerona\/glu073","article-title":"Type 2 diabetes and antidiabetic medications in relation to dementia diagnosis","volume":"69","author":"Cheng","year":"2014","journal-title":"The Journals of Gerontology. Series A, Biological Sciences and Medical Sciences"},{"issue":"10","key":"10.1016\/bs.irn.2020.02.010_bb0160","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.tem.2010.06.005","article-title":"Insulin signaling meets mitochondria in metabolism","volume":"21","author":"Cheng","year":"2010","journal-title":"Trends in Endocrinology and Metabolism"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0165","doi-asserted-by":"crossref","first-page":"322","DOI":"10.1016\/j.yexcr.2016.08.013","article-title":"Metformin activation of AMPK-dependent pathways is neuroprotective in human neural stem cells against amyloid-beta-induced mitochondrial dysfunction","volume":"347","author":"Chiang","year":"2016","journal-title":"Experimental Cell Research"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0170","doi-asserted-by":"crossref","first-page":"37","DOI":"10.14336\/AD.2017.1202","article-title":"Metformin and the risk of dementia in type 2 diabetes patients","volume":"10","author":"Chin-Hsiao","year":"2019","journal-title":"Aging and Disease"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0175","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.3233\/JAD-159002","article-title":"Long acting intranasal insulin detemir improves cognition for adults with mild cognitive impairment or early-stage Alzheimer's disease dementia","volume":"45","author":"Claxton","year":"2015","journal-title":"Journal of Alzheimer's Disease"},{"issue":"11","key":"10.1016\/bs.irn.2020.02.010_bb0180","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1093\/aje\/kwv109","article-title":"Thiazolidinediones and Parkinson Disease: A cohort study","volume":"182","author":"Connolly","year":"2015","journal-title":"American Journal of Epidemiology"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0185","doi-asserted-by":"crossref","first-page":"406","DOI":"10.2174\/1567205011310040006","article-title":"Mitochondrial abnormalities in a streptozotocin-induced rat model of sporadic Alzheimer's disease","volume":"10","author":"Correia","year":"2013","journal-title":"Current Alzheimer Research"},{"issue":"6","key":"10.1016\/bs.irn.2020.02.010_bb0190","doi-asserted-by":"crossref","first-page":"809","DOI":"10.1016\/S0306-4530(02)00087-2","article-title":"Insulin dose-response effects on memory and plasma amyloid precursor protein in Alzheimer's disease: Interactions with apolipoprotein E genotype","volume":"28","author":"Craft","year":"2003","journal-title":"Psychoneuroendocrinology"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0195","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1001\/archneurol.2011.233","article-title":"Intranasal insulin therapy for Alzheimer disease and amnestic mild cognitive impairment: A pilot clinical trial","volume":"69","author":"Craft","year":"2012","journal-title":"Archives of Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0200","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.3233\/JAD-161256","article-title":"Effects of regular and long-acting insulin on cognition and Alzheimer's disease biomarkers: A pilot clinical trial","volume":"57","author":"Craft","year":"2017","journal-title":"Journal of Alzheimer's Disease"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0205","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/0197-4580(95)02002-0","article-title":"Memory improvement following induced hyperinsulinemia in Alzheimer's disease","volume":"17","author":"Craft","year":"1996","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0210","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1007\/s40265-016-0674-0","article-title":"Insulin resistance and neurodegeneration: Progress towards the development of new therapeutics for Alzheimer's disease","volume":"77","author":"de la Monte","year":"2017","journal-title":"Drugs"},{"issue":"6","key":"10.1016\/bs.irn.2020.02.010_bb0215","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1177\/193229680800200619","article-title":"Alzheimer's disease is type 3 diabetes-evidence reviewed","volume":"2","author":"de la Monte","year":"2008","journal-title":"Journal of Diabetes Science and Technology"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0220","doi-asserted-by":"crossref","first-page":"e139","DOI":"10.1212\/WNL.0000000000005771","article-title":"Association between diabetes and subsequent Parkinson disease: A record-linkage cohort study","volume":"91","author":"De Pablo-Fernandez","year":"2018","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2020.02.010_bb0225","doi-asserted-by":"crossref","first-page":"140051","DOI":"10.1098\/rsob.140051","article-title":"PINK1 deficiency in beta-cells increases basal insulin secretion and improves glucose tolerance in mice","volume":"4","author":"Deas","year":"2014","journal-title":"Open Biology"},{"issue":"47","key":"10.1016\/bs.irn.2020.02.010_bb0230","doi-asserted-by":"crossref","first-page":"16725","DOI":"10.1523\/JNEUROSCI.2153-12.2012","article-title":"Cognitive enhancement with rosiglitazone links the hippocampal PPARgamma and ERK MAPK signaling pathways","volume":"32","author":"Denner","year":"2012","journal-title":"The Journal of Neuroscience"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0235","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1007\/s10863-019-09798-4","article-title":"Role of DJ-1 in the mechanism of pathogenesis of Parkinson's disease","volume":"51","author":"Dolgacheva","year":"2019","journal-title":"Journal of Bioenergetics and Biomembranes"},{"issue":"7","key":"10.1016\/bs.irn.2020.02.010_bb0240","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a028035","article-title":"Pathology of neurodegenerative diseases","volume":"9","author":"Dugger","year":"2017","journal-title":"Cold Spring Harbor Perspectives in Biology"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0245","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1016\/j.neurobiolaging.2013.11.001","article-title":"Dysregulation of glucose metabolism is an early event in sporadic Parkinson's disease","volume":"35","author":"Dunn","year":"2014","journal-title":"Neurobiology of Aging"},{"key":"10.1016\/bs.irn.2020.02.010_bb0250","doi-asserted-by":"crossref","first-page":"146","DOI":"10.3389\/fnagi.2019.00146","article-title":"Modifiable risk factors for Alzheimer's disease","volume":"11","author":"Edwards","year":"2019","journal-title":"Frontiers in Aging Neuroscience"},{"issue":"7","key":"10.1016\/bs.irn.2020.02.010_bb0255","doi-asserted-by":"crossref","first-page":"1593","DOI":"10.1038\/npp.2010.32","article-title":"Rosiglitazone rescues memory impairment in Alzheimer's transgenic mice: Mechanisms involving a reduced amyloid and tau pathology","volume":"35","author":"Escribano","year":"2010","journal-title":"Neuropsychopharmacology"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0260","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.mito.2008.03.004","article-title":"Mitochondrial function in Parkinson's disease cybrids containing an nt2 neuron-like nuclear background","volume":"8","author":"Esteves","year":"2008","journal-title":"Mitochondrion"},{"issue":"8","key":"10.1016\/bs.irn.2020.02.010_bb0265","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.tins.2011.05.005","article-title":"Neuroimaging markers for the prediction and early diagnosis of Alzheimer's disease dementia","volume":"34","author":"Ewers","year":"2011","journal-title":"Trends in Neurosciences"},{"issue":"6","key":"10.1016\/bs.irn.2020.02.010_bb0270","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.4103\/1673-5374.250624","article-title":"Rapid transport of insulin to the brain following intranasal administration in rats","volume":"14","author":"Fan","year":"2019","journal-title":"Neural Regeneration Research"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0275","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1016\/0006-8993(94)91698-5","article-title":"Intraventricular insulin increases dopamine transporter mRNA in rat VTA\/substantia nigra","volume":"644","author":"Figlewicz","year":"1994","journal-title":"Brain Research"},{"key":"10.1016\/bs.irn.2020.02.010_bb0280","doi-asserted-by":"crossref","first-page":"134567","DOI":"10.1016\/j.neulet.2019.134567","article-title":"Intranasal delivery of low-dose insulin ameliorates motor dysfunction and dopaminergic cell death in a 6-OHDA rat model of Parkinson's disease","volume":"714","author":"Fine","year":"2020","journal-title":"Neuroscience Letters"},{"issue":"4\u20135","key":"10.1016\/bs.irn.2020.02.010_bb0285","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1007\/s007020050068","article-title":"Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease","volume":"105","author":"Frolich","year":"1998","journal-title":"Journal of Neural Transmission (Vienna)"},{"key":"10.1016\/bs.irn.2020.02.010_bb0290","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.neurobiolaging.2018.11.008","article-title":"Intranasal insulin activates Akt2 signaling pathway in the hippocampus of wild-type but not in APP\/PS1 Alzheimer model mice","volume":"75","author":"Gabbouj","year":"2019","journal-title":"Neurobiology of Aging"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0295","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1001\/archneurol.2010.229","article-title":"A randomized pilot clinical trial of the safety of pioglitazone in treatment of patients with Alzheimer disease","volume":"68","author":"Geldmacher","year":"2011","journal-title":"Archives of Neurology"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0300","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1159\/000318845","article-title":"Rosiglitazone monotherapy in mild-to-moderate Alzheimer's disease: Results from a randomized, double-blind, placebo-controlled phase III study","volume":"30","author":"Gold","year":"2010","journal-title":"Dementia and Geriatric Cognitive Disorders"},{"issue":"6","key":"10.1016\/bs.irn.2020.02.010_bb9005","doi-asserted-by":"crossref","DOI":"10.2337\/dc13-2473","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin. Diabetes care 2013;36:2981-2987","volume":"37","author":"Goodarzi","year":"2014","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0305","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1111\/j.1471-4159.2006.04368.x","article-title":"Brain insulin system dysfunction in streptozotocin intracerebroventricularly treated rats generates hyperphosphorylated tau protein","volume":"101","author":"Grunblatt","year":"2007","journal-title":"Journal of Neurochemistry"},{"key":"10.1016\/bs.irn.2020.02.010_bb0310","doi-asserted-by":"crossref","first-page":"45971","DOI":"10.1038\/srep45971","article-title":"Long-term treatment with intranasal insulin ameliorates cognitive impairment, tau hyperphosphorylation, and microglial activation in a streptozotocin-induced Alzheimer's rat model","volume":"7","author":"Guo","year":"2017","journal-title":"Scientific Reports"},{"issue":"9","key":"10.1016\/bs.irn.2020.02.010_bb0315","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1111\/1440-1681.12265","article-title":"Metformin may produce antidepressant effects through improvement of cognitive function among depressed patients with diabetes mellitus","volume":"41","author":"Guo","year":"2014","journal-title":"Clinical and Experimental Pharmacology & Physiology"},{"issue":"6","key":"10.1016\/bs.irn.2020.02.010_bb0320","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1016\/j.neuropharm.2011.01.033","article-title":"Peripheral insulin-sensitizer drug metformin ameliorates neuronal insulin resistance and Alzheimer's-like changes","volume":"60","author":"Gupta","year":"2011","journal-title":"Neuropharmacology"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0325","doi-asserted-by":"crossref","first-page":"718","DOI":"10.1016\/j.pneurobio.2011.11.008","article-title":"The future of Alzheimer's disease: The next 10 years","volume":"95","author":"Hampel","year":"2011","journal-title":"Progress in Neurobiology"},{"issue":"Suppl. 3","key":"10.1016\/bs.irn.2020.02.010_bb0330","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1186\/1471-2202-9-S3-S5","article-title":"Intranasal delivery bypasses the blood-brain barrier to target therapeutic agents to the central nervous system and treat neurodegenerative disease","volume":"9","author":"Hanson","year":"2008","journal-title":"BMC Neuroscience"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0335","doi-asserted-by":"crossref","first-page":"592","DOI":"10.2174\/156720511796391935","article-title":"Rosiglitazone does not improve cognition or global function when used as adjunctive therapy to AChE inhibitors in mild-to-moderate Alzheimer's disease: Two phase 3 studies","volume":"8","author":"Harrington","year":"2011","journal-title":"Current Alzheimer Research"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0340","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1159\/000371509","article-title":"Effects of pioglitazone or exercise in older adults with mild cognitive impairment and insulin resistance: A pilot study","volume":"5","author":"Hildreth","year":"2015","journal-title":"Dementia and Geriatric Cognitive Disorders Extra"},{"issue":"8","key":"10.1016\/bs.irn.2020.02.010_bb0345","doi-asserted-by":"crossref","first-page":"3116","DOI":"10.1073\/pnas.1318951111","article-title":"Inhibition of p53 preserves Parkin-mediated mitophagy and pancreatic beta-cell function in diabetes","volume":"111","author":"Hoshino","year":"2014","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0350","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1016\/S0002-9440(10)64553-1","article-title":"Alpha-synuclein promotes mitochondrial deficit and oxidative stress","volume":"157","author":"Hsu","year":"2000","journal-title":"The American Journal of Pathology"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0355","doi-asserted-by":"crossref","first-page":"916","DOI":"10.1111\/j.1532-5415.2012.03916.x","article-title":"Metformin, other antidiabetic drugs, and risk of Alzheimer's disease: A population-based case-control study","volume":"60","author":"Imfeld","year":"2012","journal-title":"Journal of the American Geriatrics Society"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0360","doi-asserted-by":"crossref","first-page":"140","DOI":"10.2337\/dc14-2441","article-title":"Management of hyperglycemia in type 2 diabetes, 2015: A patient-centered approach: Update to a position statement of the American Diabetes Association and the European Association for the Study of diabetes","volume":"38","author":"Inzucchi","year":"2015","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0365","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1016\/j.bbrc.2010.12.080","article-title":"O-GlcNAcylation increases non-amyloidogenic processing of the amyloid-beta precursor protein (APP)","volume":"404","author":"Jacobsen","year":"2011","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0370","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1093\/jmcb\/mjs025","article-title":"Age- and diet-dependent requirement of DJ-1 for glucose homeostasis in mice with implications for human type 2 diabetes","volume":"4","author":"Jain","year":"2012","journal-title":"Journal of Molecular Cell Biology"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0375","first-page":"67","article-title":"p38 MAPK and PI3K\/AKT signalling cascades in Parkinson's disease","volume":"4","author":"Jha","year":"2015","journal-title":"International Journal of Molecular and Cellular Medicine"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0380","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1111\/jcpt.12808","article-title":"Scope of new formulation approaches in the repurposing of pioglitazone for the management of Alzheimer's disease","volume":"44","author":"Jojo","year":"2019","journal-title":"Journal of Clinical Pharmacy and Therapeutics"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0385","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.bbrc.2005.11.177","article-title":"Rosiglitazone protects human neuroblastoma SH-SY5Y cells against acetaldehyde-induced cytotoxicity","volume":"340","author":"Jung","year":"2006","journal-title":"Biochemical and Biophysical Research Communications"},{"issue":"1\u20132","key":"10.1016\/bs.irn.2020.02.010_bb9020","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.jns.2006.11.020","article-title":"Rosiglitazone protects human neuroblastoma SH-SY5Y cells against MPP+ induced cytotoxicity via inhibition of mitochondrial dysfunction and ROS production","volume":"253","author":"Jung","year":"2007","journal-title":"Journal of the Neurological Sciences"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0390","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jalz.2017.02.006","article-title":"Alzheimer's disease: The next frontier-special report 2017","volume":"13","author":"Karlawish","year":"2017","journal-title":"Alzheimers Dement"},{"key":"10.1016\/bs.irn.2020.02.010_bb0395","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.neuroscience.2015.03.017","article-title":"Dysregulation of parkin in the substantia nigra of db\/db and high-fat diet mice","volume":"294","author":"Khang","year":"2015","journal-title":"Neuroscience"},{"issue":"50","key":"10.1016\/bs.irn.2020.02.010_bb0400","doi-asserted-by":"crossref","first-page":"21830","DOI":"10.1073\/pnas.0912793107","article-title":"Biguanide metformin acts on tau phosphorylation via mTOR\/protein phosphatase 2A (PP2A) signaling","volume":"107","author":"Kickstein","year":"2010","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0405","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.22383","article-title":"Dopaminergic pathway reconstruction by Akt\/Rheb-induced axon regeneration","volume":"70","author":"Kim","year":"2011","journal-title":"Annals of Neurology"},{"key":"10.1016\/bs.irn.2020.02.010_bb0410","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1016\/j.nbd.2019.02.020","article-title":"Genetic suppression of IKK2\/NF-kappaB in astrocytes inhibits neuroinflammation and reduces neuronal loss in the MPTP-probenecid model of Parkinson's disease","volume":"127","author":"Kirkley","year":"2019","journal-title":"Neurobiology of Disease"},{"issue":"7","key":"10.1016\/bs.irn.2020.02.010_bb0415","doi-asserted-by":"crossref","first-page":"2232","DOI":"10.2337\/db14-0568","article-title":"Insulin action in brain regulates systemic metabolism and brain function","volume":"63","author":"Kleinridders","year":"2014","journal-title":"Diabetes"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0420","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1097\/WAD.0000000000000202","article-title":"Effects of the insulin sensitizer metformin in Alzheimer disease: Pilot data from a randomized placebo-controlled crossover study","volume":"31","author":"Koenig","year":"2017","journal-title":"Alzheimer Disease and Associated Disorders"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0425","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1152\/physrev.00032.2015","article-title":"Brain insulin resistance at the crossroads of metabolic and cognitive disorders in humans","volume":"96","author":"Kullmann","year":"2016","journal-title":"Physiological Reviews"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0430","doi-asserted-by":"crossref","first-page":"13","DOI":"10.3233\/JAD-2006-9102","article-title":"Intracerebral streptozotocin model of type 3 diabetes: Relevance to sporadic Alzheimer's disease","volume":"9","author":"Lester-Coll","year":"2006","journal-title":"Journal of Alzheimer's Disease"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0435","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1016\/j.pbb.2012.03.002","article-title":"Metformin attenuates Alzheimer's disease-like neuropathology in obese, leptin-resistant mice","volume":"101","author":"Li","year":"2012","journal-title":"Pharmacology, Biochemistry, and Behavior"},{"issue":"Pt. 7","key":"10.1016\/bs.irn.2020.02.010_bb0440","doi-asserted-by":"crossref","first-page":"1820","DOI":"10.1093\/brain\/awp099","article-title":"Reduced O-GlcNAcylation links lower brain glucose metabolism and tau pathology in Alzheimer's disease","volume":"132","author":"Liu","year":"2009","journal-title":"Brain"},{"issue":"9","key":"10.1016\/bs.irn.2020.02.010_bb0445","doi-asserted-by":"crossref","DOI":"10.1093\/ijnp\/pyw047","article-title":"Metformin prevents dopaminergic neuron death in MPTP\/P-induced mouse model of Parkinson's disease via autophagy and mitochondrial ROS clearance","volume":"19","author":"Lu","year":"2016","journal-title":"The International Journal of Neuropsychopharmacology"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0450","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1097\/MAJ.0000000000000499","article-title":"Rosiglitazone improves learning and memory ability in rats with type 2 diabetes through the insulin signaling pathway","volume":"350","author":"Ma","year":"2015","journal-title":"The American Journal of the Medical Sciences"},{"issue":"53","key":"10.1016\/bs.irn.2020.02.010_bb0455","doi-asserted-by":"crossref","first-page":"14363","DOI":"10.1523\/JNEUROSCI.3928-08.2008","article-title":"RTP801 is induced in Parkinson's disease and mediates neuron death by inhibiting Akt phosphorylation\/activation","volume":"28","author":"Malagelada","year":"2008","journal-title":"The Journal of Neuroscience"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0460","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1385\/NMM:5:2:147","article-title":"Differential expression of oxidative phosphorylation genes in patients with Alzheimer's disease: Implications for early mitochondrial dysfunction and oxidative damage","volume":"5","author":"Manczak","year":"2004","journal-title":"Neuromolecular Medicine"},{"issue":"23","key":"10.1016\/bs.irn.2020.02.010_bb0465","doi-asserted-by":"crossref","first-page":"5131","DOI":"10.1093\/hmg\/dds360","article-title":"Abnormal interaction of VDAC1 with amyloid beta and phosphorylated tau causes mitochondrial dysfunction in Alzheimer's disease","volume":"21","author":"Manczak","year":"2012","journal-title":"Human Molecular Genetics"},{"issue":"12","key":"10.1016\/bs.irn.2020.02.010_bb0470","doi-asserted-by":"crossref","first-page":"2614","DOI":"10.1007\/s11095-017-2199-y","article-title":"Metformin - a future therapy for neurodegenerative diseases: Theme: Drug discovery, development and delivery in Alzheimer's disease guest editor: Davide Brambilla","volume":"34","author":"Markowicz-Piasecka","year":"2017","journal-title":"Pharmaceutical Research"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0475","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1016\/j.neurobiolaging.2008.04.002","article-title":"Defects in IGF-1 receptor, insulin receptor and IRS-1\/2 in Alzheimer's disease indicate possible resistance to IGF-1 and insulin signalling","volume":"31","author":"Moloney","year":"2010","journal-title":"Neurobiology of Aging"},{"issue":"10","key":"10.1016\/bs.irn.2020.02.010_bb0480","doi-asserted-by":"crossref","first-page":"2981","DOI":"10.2337\/dc13-0229","article-title":"Increased risk of cognitive impairment in patients with diabetes is associated with metformin","volume":"36","author":"Moore","year":"2013","journal-title":"Diabetes Care"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb9030","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/ng1180","article-title":"PGC-1alpha-responsive genes involved in oxidative phosphorylation are coordinately downregulated in human diabetes","volume":"34","author":"Mootha","year":"2003","journal-title":"Nature Genetics"},{"issue":"12","key":"10.1016\/bs.irn.2020.02.010_bb0485","doi-asserted-by":"crossref","first-page":"4036","DOI":"10.2337\/dc13-0143","article-title":"Brain atrophy in type 2 diabetes: Regional distribution and influence on cognition","volume":"36","author":"Moran","year":"2013","journal-title":"Diabetes Care"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0490","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1007\/BF00313602","article-title":"Loss of insulin receptor immunoreactivity from the substantia nigra pars compacta neurons in Parkinson's disease","volume":"87","author":"Moroo","year":"1994","journal-title":"Acta Neuropathologica"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0495","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1016\/j.expneurol.2011.06.005","article-title":"Insulin resistance impairs nigrostriatal dopamine function","volume":"231","author":"Morris","year":"2011","journal-title":"Experimental Neurology"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0500","doi-asserted-by":"crossref","first-page":"R1082","DOI":"10.1152\/ajpregu.00449.2010","article-title":"Neurodegeneration in an animal model of Parkinson's disease is exacerbated by a high-fat diet","volume":"299","author":"Morris","year":"2010","journal-title":"American Journal of Physiology. Regulatory, Integrative and Comparative Physiology"},{"issue":"9","key":"10.1016\/bs.irn.2020.02.010_bb0505","doi-asserted-by":"crossref","first-page":"14318","DOI":"10.1002\/jcb.28094","article-title":"A shared comparison of diabetes mellitus and neurodegenerative disorders","volume":"120","author":"Morsi","year":"2019","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0510","doi-asserted-by":"crossref","first-page":"61","DOI":"10.3233\/JAD-131901","article-title":"Long-term metformin usage and cognitive function among older adults with diabetes","volume":"41","author":"Ng","year":"2014","journal-title":"Journal of Alzheimer's Disease"},{"issue":"8","key":"10.1016\/bs.irn.2020.02.010_bb0515","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S1474-4422(15)00144-1","article-title":"Pioglitazone in early Parkinson's disease: A phase 2, multicentre, double-blind, randomised trial","volume":"14","author":"NINDS Exploratory Trials in Parkinson Disease (NET-PD) FS-ZONE Investigators","year":"2015","journal-title":"Lancet Neurology"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0520","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1089\/ars.2006.1458","article-title":"Impact of mitochondrial ROS production in the pathogenesis of diabetes mellitus and its complications","volume":"9","author":"Nishikawa","year":"2007","journal-title":"Antioxidants & Redox Signaling"},{"key":"10.1016\/bs.irn.2020.02.010_bb0525","first-page":"683","article-title":"Management of type 2 diabetes mellitus. Role of thiazolidinediones","volume":"51","author":"Noble","year":"2005","journal-title":"Canadian Family Physician"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0530","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0214364","article-title":"Safety and preliminary efficacy of intranasal insulin for cognitive impairment in Parkinson disease and multiple system atrophy: A double-blinded placebo-controlled pilot study","volume":"14","author":"Novak","year":"2019","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.irn.2020.02.010_bb0535","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1212\/WNL.53.9.1937","article-title":"Diabetes mellitus and the risk of dementia: The Rotterdam study","volume":"53","author":"Ott","year":"1999","journal-title":"Neurology"},{"key":"10.1016\/bs.irn.2020.02.010_bb0540","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.bbi.2017.12.009","article-title":"Metformin treatment prevents amyloid plaque deposition and memory impairment in APP\/PS1 mice","volume":"69","author":"Ou","year":"2018","journal-title":"Brain, Behavior, and Immunity"},{"issue":"19","key":"10.1016\/bs.irn.2020.02.010_bb0545","doi-asserted-by":"crossref","first-page":"e1654","DOI":"10.1212\/WNL.0000000000005475","article-title":"Diabetes mellitus and Parkinson disease","volume":"90","author":"Pagano","year":"2018","journal-title":"Neurology"},{"issue":"18","key":"10.1016\/bs.irn.2020.02.010_bb0550","doi-asserted-by":"crossref","first-page":"18614","DOI":"10.1074\/jbc.M401135200","article-title":"Mitochondrial dysfunction and oxidative damage in parkin-deficient mice","volume":"279","author":"Palacino","year":"2004","journal-title":"The Journal of Biological Chemistry"},{"key":"10.1016\/bs.irn.2020.02.010_bb0555","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.neuroscience.2016.01.020","article-title":"Intranasal insulin protects against substantia nigra dopaminergic neuronal loss and alleviates motor deficits induced by 6-OHDA in rats","volume":"318","author":"Pang","year":"2016","journal-title":"Neuroscience"},{"key":"10.1016\/bs.irn.2020.02.010_bb0560","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/j.neuroscience.2014.07.046","article-title":"Neuroprotective effect of metformin in MPTP-induced Parkinson's disease in mice","volume":"277","author":"Patil","year":"2014","journal-title":"Neuroscience"},{"key":"10.1016\/bs.irn.2020.02.010_bb0565","doi-asserted-by":"crossref","first-page":"104593","DOI":"10.1016\/j.phrs.2019.104593","article-title":"Emerging neuroprotective effect of metformin in Parkinson's disease: A molecular crosstalk","volume":"152","author":"Paudel","year":"2020","journal-title":"Pharmacological Research"},{"key":"10.1016\/bs.irn.2020.02.010_bb0570","doi-asserted-by":"crossref","DOI":"10.1038\/cddis.2014.175","article-title":"Metformin lowers Ser-129 phosphorylated alpha-synuclein levels via mTOR-dependent protein phosphatase 2A activation","volume":"5","author":"Perez-Revuelta","year":"2014","journal-title":"Cell Death & Disease"},{"issue":"8","key":"10.1016\/bs.irn.2020.02.010_bb0575","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1016\/j.bbadis.2018.10.037","article-title":"Diminished O-GlcNAcylation in Alzheimer's disease is strongly correlated with mitochondrial anomalies","volume":"1865","author":"Pinho","year":"2019","journal-title":"Biochimica et Biophysica Acta - Molecular Basis of Disease"},{"key":"10.1016\/bs.irn.2020.02.010_bb0580","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1016\/j.arr.2018.05.003","article-title":"O-GlcNAcylation and neuronal energy status: Implications for Alzheimer's disease","volume":"46","author":"Pinho","year":"2018","journal-title":"Ageing Research Reviews"},{"key":"10.1016\/bs.irn.2020.02.010_bb0585","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1186\/s13024-016-0090-7","article-title":"Pioglitazone ameliorates the phenotype of a novel Parkinson's disease mouse model by reducing neuroinflammation","volume":"11","author":"Pinto","year":"2016","journal-title":"Molecular Neurodegeneration"},{"issue":"8","key":"10.1016\/bs.irn.2020.02.010_bb0590","doi-asserted-by":"crossref","first-page":"6507","DOI":"10.1007\/s12035-016-0169-8","article-title":"Intranasal insulin administration ameliorates streptozotocin (ICV)-induced insulin receptor dysfunction, neuroinflammation, amyloidogenesis, and memory impairment in rats","volume":"54","author":"Rajasekar","year":"2017","journal-title":"Molecular Neurobiology"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0595","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1002\/jcb.25376","article-title":"The neuroprotective role of insulin against MPP(+)-induced Parkinson's disease in differentiated SH-SY5Y cells","volume":"117","author":"Ramalingam","year":"2016","journal-title":"Journal of Cellular Biochemistry"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb9040","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3109\/10799893.2016.1171342","article-title":"Protective effects of activated signaling pathways by insulin on C6 glial cell model of MPP+-induced Parkinson's disease","volume":"37","author":"Ramalingam","year":"2017","journal-title":"Journal of Receptor and Signal Transduction Research"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0600","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1016\/j.neurobiolaging.2005.03.016","article-title":"Effects of intranasal insulin on cognition in memory-impaired older adults: Modulation by APOE genotype","volume":"27","author":"Reger","year":"2006","journal-title":"Neurobiology of Aging"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0605","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1038\/sj.tpj.6500369","article-title":"Efficacy of rosiglitazone in a genetically defined population with mild-to-moderate Alzheimer's disease","volume":"6","author":"Risner","year":"2006","journal-title":"The Pharmacogenomics Journal"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0610","doi-asserted-by":"crossref","first-page":"247","DOI":"10.3233\/JAD-2005-8304","article-title":"Insulin and insulin-like growth factor expression and function deteriorate with progression of Alzheimer's disease: Link to brain reductions in acetylcholine","volume":"8","author":"Rivera","year":"2005","journal-title":"Journal of Alzheimer's Disease"},{"issue":"3","key":"10.1016\/bs.irn.2020.02.010_bb0615","doi-asserted-by":"crossref","first-page":"307","DOI":"10.2174\/157339906777950651","article-title":"Metformin beyond diabetes: New life for an old drug","volume":"2","author":"Rotella","year":"2006","journal-title":"Current Diabetes Reviews"},{"key":"10.1016\/bs.irn.2020.02.010_bb0620","doi-asserted-by":"crossref","first-page":"400","DOI":"10.3389\/fendo.2018.00400","article-title":"The therapeutic potential of metformin in neurodegenerative diseases","volume":"9","author":"Rotermund","year":"2018","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"10.1016\/bs.irn.2020.02.010_bb0625","article-title":"Neuroprotective effect of metformin on dopaminergic neurodegeneration and alpha-synuclein aggregation in C. elegans model of Parkinson's disease","author":"Saewanee","year":"2019","journal-title":"Neuroscience Research"},{"issue":"1\u20134","key":"10.1016\/bs.irn.2020.02.010_bb0630","doi-asserted-by":"crossref","first-page":"125","DOI":"10.3109\/00207459309003322","article-title":"The relationship between diabetes mellitus and Parkinson's disease","volume":"69","author":"Sandyk","year":"1993","journal-title":"The International Journal of Neuroscience"},{"issue":"12","key":"10.1016\/bs.irn.2020.02.010_bb0635","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0083940","article-title":"Integrative network analysis unveils convergent molecular pathways in Parkinson's disease and diabetes","volume":"8","author":"Santiago","year":"2013","journal-title":"PLoS One"},{"issue":"9","key":"10.1016\/bs.irn.2020.02.010_bb0640","doi-asserted-by":"crossref","first-page":"1626","DOI":"10.1016\/j.neurobiolaging.2009.10.009","article-title":"Efficacy of PPAR-gamma agonist pioglitazone in mild Alzheimer disease","volume":"32","author":"Sato","year":"2011","journal-title":"Neurobiology of Aging"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0645","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1111\/j.1460-9568.2009.06657.x","article-title":"PPAR-gamma-mediated neuroprotection in a chronic mouse model of Parkinson's disease","volume":"29","author":"Schintu","year":"2009","journal-title":"The European Journal of Neuroscience"},{"key":"10.1016\/bs.irn.2020.02.010_bb0650","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1097\/00005053-196006000-00017","article-title":"Progression and prognosis in Parkinson's disease","volume":"130","author":"Schwab","year":"1960","journal-title":"The Journal of Nervous and Mental Disease"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0655","doi-asserted-by":"crossref","first-page":"943","DOI":"10.3233\/JAD-2012-111661","article-title":"Long-term pioglitazone treatment improves learning and attenuates pathological markers in a mouse model of Alzheimer's disease","volume":"30","author":"Searcy","year":"2012","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/bs.irn.2020.02.010_bb0660","first-page":"110","article-title":"Insulin as a bridge between type 2 diabetes and Alzheimer disease\u2014How anti-diabetics could be a solution for dementia","volume":"5","author":"Sebastiao","year":"2014","journal-title":"Frontiers in Endocrinology (Lausanne)"},{"key":"10.1016\/bs.irn.2020.02.010_bb0665","doi-asserted-by":"crossref","first-page":"302","DOI":"10.3389\/fnagi.2019.00302","article-title":"Diabetes, a contemporary risk for Parkinson's disease: Epidemiological and cellular evidences","volume":"11","author":"Sergi","year":"2019","journal-title":"Frontiers in Aging Neuroscience"},{"key":"10.1016\/bs.irn.2020.02.010_bb0670","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.bbr.2018.05.025","article-title":"High fat diet feeding induced insulin resistance exacerbates 6-OHDA mediated neurotoxicity and behavioral abnormalities in rats","volume":"351","author":"Sharma","year":"2018","journal-title":"Behavioural Brain Research"},{"issue":"2","key":"10.1016\/bs.irn.2020.02.010_bb0675","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1210\/jc.2011-1802","article-title":"Effect of intranasal insulin on cognitive function: A systematic review","volume":"97","author":"Shemesh","year":"2012","journal-title":"The Journal of Clinical Endocrinology and Metabolism"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0680","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1007\/s12035-019-01858-5","article-title":"Alzheimer's disease and diabetes: Insulin signaling as the bridge linking two pathologies","volume":"57","author":"Shieh","year":"2020","journal-title":"Molecular Neurobiology"},{"issue":"5","key":"10.1016\/bs.irn.2020.02.010_bb0685","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1002\/ana.410350507","article-title":"Decreased concentrations of GLUT1 and GLUT3 glucose transporters in the brains of patients with Alzheimer's disease","volume":"35","author":"Simpson","year":"1994","journal-title":"Annals of Neurology"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0690","doi-asserted-by":"crossref","first-page":"14038","DOI":"10.1038\/s41598-017-14420-x","article-title":"Late-onset Alzheimer's disease is associated with inherent changes in bioenergetics profiles","volume":"7","author":"Sonntag","year":"2017","journal-title":"Scientific Reports"},{"issue":"1","key":"10.1016\/bs.irn.2020.02.010_bb0695","doi-asserted-by":"crossref","first-page":"63","DOI":"10.3233\/JAD-2005-7107","article-title":"Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease\u2014Is this type 3 diabetes?","volume":"7","author":"Steen","year":"2005","journal-title":"Journal of Alzheimer's Disease"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0700","doi-asserted-by":"crossref","first-page":"1316","DOI":"10.1172\/JCI59903","article-title":"Demonstrated brain insulin resistance in Alzheimer's disease patients is associated with IGF-1 resistance, IRS-1 dysregulation, and cognitive decline","volume":"122","author":"Talbot","year":"2012","journal-title":"The Journal of Clinical Investigation"},{"key":"10.1016\/bs.irn.2020.02.010_bb0705","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/B978-0-444-53480-4.00035-7","article-title":"Diabetes and neurodegeneration in the brain","volume":"126","author":"Toth","year":"2014","journal-title":"Handbook of Clinical Neurology"},{"issue":"9","key":"10.1016\/bs.irn.2020.02.010_bb0710","doi-asserted-by":"crossref","first-page":"2724","DOI":"10.18632\/aging.101944","article-title":"Rosiglitazone has a neutral effect on the risk of dementia in type 2 diabetes patients","volume":"11","author":"Tseng","year":"2019","journal-title":"Aging (Albany NY)"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0715","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.3233\/JAD-2010-100939","article-title":"A multi-center randomized proof-of-concept clinical trial applying [(1)(8)F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease","volume":"22","author":"Tzimopoulou","year":"2010","journal-title":"Journal of Alzheimer's Disease"},{"key":"10.1016\/bs.irn.2020.02.010_bb0720","doi-asserted-by":"crossref","first-page":"465","DOI":"10.3389\/fnmol.2018.00465","article-title":"Could alpha-synuclein modulation of insulin and dopamine identify a novel link between Parkinson's disease and diabetes as well as potential therapies?","volume":"11","author":"Vidal-Martinez","year":"2018","journal-title":"Frontiers in Molecular Neuroscience"},{"issue":"7399","key":"10.1016\/bs.irn.2020.02.010_bb0725","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/485426a","article-title":"US Government sets out Alzheimer's plan","volume":"485","author":"Wadman","year":"2012","journal-title":"Nature"},{"issue":"6","key":"10.1016\/bs.irn.2020.02.010_bb0730","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.parkreldis.2012.03.010","article-title":"Metformin-inclusive sulfonylurea therapy reduces the risk of Parkinson's disease occurring with type 2 diabetes in a Taiwanese population cohort","volume":"18","author":"Wahlqvist","year":"2012","journal-title":"Parkinsonism & Related Disorders"},{"issue":"9","key":"10.1016\/bs.irn.2020.02.010_bb0735","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/j.freeradbiomed.2011.01.032","article-title":"Impaired CD200-CD200R-mediated microglia silencing enhances midbrain dopaminergic neurodegeneration: Roles of aging, superoxide, NADPH oxidase, and p38 MAPK","volume":"50","author":"Wang","year":"2011","journal-title":"Free Radical Biology & Medicine"},{"issue":"11","key":"10.1016\/bs.irn.2020.02.010_bb0740","first-page":"950","article-title":"Preserved cognition in patients with early Alzheimer disease and amnestic mild cognitive impairment during treatment with rosiglitazone: A preliminary study","volume":"13","author":"Watson","year":"2005","journal-title":"The American Journal of Geriatric Psychiatry"},{"issue":"6","key":"10.1016\/bs.irn.2020.02.010_bb0745","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.2337\/db14-1507","article-title":"Insulin resistance predicts medial temporal hypermetabolism in mild cognitive impairment conversion to Alzheimer disease","volume":"64","author":"Willette","year":"2015","journal-title":"Diabetes"},{"issue":"8","key":"10.1016\/bs.irn.2020.02.010_bb0750","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2018-023302","article-title":"Pioglitazone use and Parkinson's disease: A retrospective cohort study in Taiwan","volume":"8","author":"Wu","year":"2018","journal-title":"BMJ Open"},{"key":"10.1016\/bs.irn.2020.02.010_bb0755","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/1742-2094-5-4","article-title":"Pioglitazone inhibition of lipopolysaccharide-induced nitric oxide synthase is associated with altered activity of p38 MAP kinase and PI3K\/Akt","volume":"5","author":"Xing","year":"2008","journal-title":"Journal of Neuroinflammation"},{"issue":"8","key":"10.1016\/bs.irn.2020.02.010_bb0760","doi-asserted-by":"crossref","first-page":"1680","DOI":"10.1016\/j.cellsig.2014.04.009","article-title":"Activation of AMPK and inactivation of Akt result in suppression of mTOR-mediated S6K1 and 4E-BP1 pathways leading to neuronal cell death in in vitro models of Parkinson's disease","volume":"26","author":"Xu","year":"2014","journal-title":"Cellular Signalling"},{"issue":"4","key":"10.1016\/bs.irn.2020.02.010_bb0765","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1007\/s00702-014-1294-z","article-title":"Insulin sensitizers improve learning and attenuate tau hyperphosphorylation and neuroinflammation in 3xTg-AD mice","volume":"122","author":"Yu","year":"2015","journal-title":"Journal of Neural Transmission (Vienna)"},{"issue":"18","key":"10.1016\/bs.irn.2020.02.010_bb0770","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000003549","article-title":"Risk of Parkinson disease in diabetes mellitus: An updated meta-analysis of population-based cohort studies","volume":"95","author":"Yue","year":"2016","journal-title":"Medicine (Baltimore)"}],"container-title":["International Review of Neurobiology","Metabolic and Bioenergetic Drivers of Neurodegenerative Disease: Treating neurodegenerative diseases as metabolic diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774220300192?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0074774220300192?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,24]],"date-time":"2025-09-24T21:13:27Z","timestamp":1758748407000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0074774220300192"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020]]},"ISBN":["9780128231210"],"references-count":158,"URL":"https:\/\/doi.org\/10.1016\/bs.irn.2020.02.010","relation":{},"ISSN":["0074-7742"],"issn-type":[{"value":"0074-7742","type":"print"}],"subject":[],"published":{"date-parts":[[2020]]}}}